Now showing items 1-4 of 4

    • Evaluation of the Response of Intracranial Xenografts to VEGF Signaling Inhibition Using Multiparametric MRI. 

      Boult, JKR; Box, G; Vinci, M; Perryman, L; Eccles, SA; Jones, C; Robinson, SP (2017-09)
      Vascular endothelial growth factor A (VEGF-A) is considered one of the most important factors in tumor angiogenesis, and consequently, a number of therapeutics have been developed to inhibit VEGF signaling. Therapeutic ...
    • Genomic gain and over expression of CCL2 correlate with vascular invasion in stage I non-seminomatous testicular germ-cell tumours. 

      Gilbert, DC; Chandler, I; Summersgill, B; McIntyre, A; Missiaglia, E; Goddard, NC; Huddart, RA; Shipley, J (2011-08)
      Testicular germ-cell tumours (TGCT) are the most frequent solid tumour to affect young Caucasian adult males and have increased in incidence over recent decades. In clinical stage I non-seminomas, (NSGCT) histological ...
    • Individualized dosing with axitinib: rationale and practical guidance. 

      Schmidinger, M; Danesi, R; Jones, R; McDermott, R; Pyle, L; Rini, B; Négrier, S (2018-04)
      Axitinib is a potent, selective, vascular endothelial growth factor receptor inhibitor with demonstrated efficacy as second-line treatment for metastatic renal cell carcinoma. Analyses of axitinib drug exposures have ...
    • Renal cell carcinoma. 

      Hsieh, JJ; Purdue, MP; Signoretti, S; Swanton, C; Albiges, L; Schmidinger, M; Heng, DY; Larkin, J; Ficarra, V (2017-03-09)
      Renal cell carcinoma (RCC) denotes cancer originated from the renal epithelium and accounts for >90% of cancers in the kidney. The disease encompasses >10 histological and molecular subtypes, of which clear cell RCC (ccRCC) ...